Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
about
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014.Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patientsCan the breast screening appointment be used to provide risk assessment and prevention advice?Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention.Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.Precision Medicine Meets Public Health: Population Screening for BRCA1 and BRCA2
P2860
Q34042627-2419C74C-2582-41DD-B508-1BFCB4061F7DQ34354614-FF91D430-579B-4C20-A3FB-DACDBEC53ECDQ35603681-400D142E-E8A9-49F0-B67E-128A029265B9Q35834376-775C9DC2-F69F-46A8-AB45-9840BE632EFFQ37433766-74C5B302-81AA-44F1-9E30-999233F8E3E5Q50091589-A4837553-B15A-4183-99E0-845DF305CD30Q57499876-8A917628-98AF-44BB-8953-577C1C1E8657
P2860
Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Which screening strategy shoul ...... omparative cost-effectiveness.
@en
type
label
Which screening strategy shoul ...... omparative cost-effectiveness.
@en
prefLabel
Which screening strategy shoul ...... omparative cost-effectiveness.
@en
P2093
P2860
P356
P1476
Which screening strategy shoul ...... comparative cost-effectiveness
@en
P2093
J C Oosterwijk
K M Vermeulen
M D Dorrius
M J W Greuter
N Houssami
S Siesling
P2860
P2888
P304
P356
10.1038/BJC.2013.149
P407
P577
2013-04-11T00:00:00Z